Organic Chemical – Page 3

Pfizer, Astellas’ Xtandi Combo Extends Survival in Early Prostate Cancer

2 weeks ago talkbio0Tagged Astellas, BCR, biochemical recurrence, Combined Modality Therapy, EMBARK, enzalutamide, leuprolide, Malignant neoplasm of prostate, nmHSPC, non-metastatic, Overall Survival, Pfizer, Xtandi

Pfizer; Astellas; Xtandi; Enzalutamide; prostate cancer; overall survival; combination therapy; leuprolide; non-metastatic hormone-sensitive prostate cancer (nmHSPC); EMBARK study; biochemical recurrence (BCR)

Deal Roundup: Novartis Options Sironax’s Neuro Platform, Plus Moves from Revolution, Iambic, Sernova, and Eledon

2 weeks ago talkbio0Tagged Blood - brain barrier anatomy, Brain Delivery Module, dealmaking, Eledon, Iambic, Neuroscience discipline, Novartis, Revolution Medicines, Sernova, Sironax

Novartis; Sironax; Brain Delivery Module; neuroscience; blood-brain barrier; biotech; dealmaking; Revolution Medicines; Iambic; Sernova; Eledon

Revolution Medicines and Iambic Announce $25M AI-Powered Drug Discovery Collaboration

2 weeks ago talkbio0Tagged Aortic Valve Insufficiency, Artificial Intelligence, Collaboration, Drug Discovery, Drug Industry, Iambic Therapeutics, milestone payments, Neoplasms, NeuralPLexer, propane, RAS-addicted cancers, Revolution Medicines

Revolution Medicines; Iambic Therapeutics; AI drug discovery; NeuralPLexer; PropANE; oncology; RAS-addicted cancers; collaboration; pharmaceutical industry; milestone payments

Taiho’s Investigational DMD Therapy Misses Primary Endpoint in Phase 3 Trial

3 weeks ago talkbio0Tagged Clinical trial failure, Muscular Dystrophy, Duchenne, Otsuka Holdings, pizuglanstat, REACH-DMD study, Taiho, TAS-205

Taiho; Duchenne muscular dystrophy; DMD; pizuglanstat; TAS-205; Phase 3 trial; clinical trial failure; REACH-DMD study; Otsuka Holdings

Novartis Gains World-First Approval of Malaria Treatment for Babies

3 weeks ago talkbio0Tagged Africa, Approved, artemether-lumefantrine, Coartem, Infant, Infant, Newborn, Malaria, Novartis, Swissmedic, venture

Novartis; malaria; Coartem Baby; Swissmedic; newborns; infants; Africa; approval; artemether-lumefantrine; Medicines for Malaria Venture; not-for-profit

China Approves Lilly and Innovent’s Mazdutide, Marking New Era for GLP-1 Obesity Drugs

4 weeks ago talkbio0Tagged China approval, eli lilly, GCG, GCG/GLP-1 agonist, Glucagon-Like Peptide 1, Innovent Biologics, mazdutide, N-methyl-N-2-(methylsulfinyl)ethylpropionic acid amide, Obesity, Weight maintenance regimen

Mazdutide; China approval; Innovent Biologics; Eli Lilly; GLP-1 obesity drugs; dual GCG/GLP-1 agonist; NMPA; weight management

RFK Jr.’s Revamped ACIP Votes Against Thimerosal in Flu Vaccines, Signaling Shift in Vaccine Policy

4 weeks ago talkbio0Tagged ACIP, Advisory Committees, anti-vaccine movement, Centers for Disease Control and Prevention (U.S.), Immunization, Influenza virus vaccine, Policy, Practice Experience, Respiratory syncytial virus, RFK Jr., thimerosal, Vaccines

RFK Jr.; ACIP; thimerosal; flu vaccine; vaccine policy; anti-vaccine movement; CDC; RSV shot; Advisory Committee on Immunization Practices

Trump’s CDC Nominee Susan Monarez Affirms Vaccine Safety and Access Commitment

4 weeks ago talkbio0Tagged alliance, Autistic Disorder, Centers for Disease Control and Prevention (U.S.), Confirmation, Gavi Vaccine, Monarez, Nominee, Robert F. Kennedy Jr., Senate, Susan, Trump administration, Vaccine Safety, Vaccines

Susan Monarez; CDC nominee; vaccines; Trump administration; vaccine safety; autism; Senate confirmation; Robert F. Kennedy Jr.; Gavi Vaccine Alliance

Novartis and ProFound Therapeutics Forge $750M-Per-Target Cardiovascular Pact

1 month ago talkbio0Tagged biobucks, biotech partnership, Cardiovascular Diseases, Drug Discovery, Flagship, Novartis, pharmaceutical milestones, ProFound Therapeutics, Proteomics

Novartis; ProFound Therapeutics; cardiovascular disease; biotech partnership; drug discovery; proteomics; biobucks; flagship pioneering; pharmaceutical milestones

TIGIT Turmoil: How Pharma Burned Billions on Failed Immuno-Oncology Projects

1 month ago talkbio0Tagged Arcus Biosciences, Clinical Trials, Gilead, immuno-oncology, iTeos, Merck, Myers, Novartis, Pharma, Roche (company), SmithKline Beecham, squibb, TIGIT gene, Tiragolumab

TIGIT; immuno-oncology; failed clinical trials; pharma investment loss; Gilead; GSK; Bristol Myers Squibb; Novartis; Merck; Roche; iTeos; Arcus Biosciences; tiragolumab; belrestotug